Strict new conflict of interest rules for MHRA proposed
November 19, 2004Growing concerns about the independence and transparency of the UK medicines regulator have been met by a set of strict …
Raptiva launched in first European markets
November 18, 2004Serono's new psoriasis treatment Raptiva has been launched in its first European markets, including the UK.The drug is licensed to …
Mutual medicine
November 18, 2004From developing strategy for a product at the earliest pre-launch phase to promoting older, established products the pharma industry has …
PR: the power of perceptions
November 3, 2004Pharma is taking an increasing interest in PR and what it can achieve in the marketing mix. But with a …
Lilly’s Alimta ready for UK launch
November 2, 2004Lilly's chemotherapy drug Alimta is to be launched in the UK for the treatment of malignant pleural mesothelioma, a type …
Mission to maximise
November 2, 2004We all know that 'less is more'. What clearer mission could you have as a marketer – take this product …
Black box warning for antidepressants in US
November 2, 2004The industry's biggest selling antidepressants will all have to carry the strongest possible warnings in the US, after the FDA …
Industry ready to reply after critics savage practices
November 2, 2004UK regulator the MHRA and the pharmaceutical industry have been condemned for being engaged in a closed and uncritical relationship, …
Lonngren lashes out at late warning
November 1, 2004EMA, EMEA, Lonngren, Vioxx
Thomas Lonngren, the head of Europe’s medicines regulator the EMEA has spoken out about Merck’s withdrawal of Vioxx, saying the …
Nanotechnology: small could be big
October 27, 2004Nanotechnology is starting to fuel the imagination and commercial aspirations of pharma companies, but sound strategies for intellectual property protection …
Pfizer warns of slowdown in 2005
October 27, 2004Pfizer has warned that growth in 2005 could be held back by generic competition and other increasing market pressures.The company's …
Prexige launch delayed
October 27, 2004Novartis has delayed the launch of its potential blockbuster painkiller Prexige until 2007, in the wake of Vioxx's withdrawal. The …
Latest content
FibroFind appoints Lee Borthwick as CEO
